Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

Oncology Pipeline & Trials

Oncology Pipeline Snapshot as of July 31, 2018

Download Complete Pipeline PDF

Discovery Projects
Phase 1

15
Phase 2

6
Phase 3

17
Registration

5
Total43

Compound Name	Indication	Phase	Submission Type	Compound Type
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Merkel Cell Carcinoma (E.U.) (Biologic)	Phase 2	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ PF-04518600 (OX40) for: Squamous Cell Carcinoma of the Head and Neck (Biologic)	Phase 2	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ PF-05082566 (4-1BB) for: Melanoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Triple-Negative Breast Cancer (Biologic)	Phase 2	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ PF-04518600 (OX40) and PF-05082566 (4-1BB) for: Cancer (Biologic)	Phase 1	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ talazoparib (MDV3800) for: Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) Project advanced	Phase 2	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ talazoparib (MDV3800) for: Solid Tumors with a BRCA or ATM defect (Biologic) Project advanced	Phase 2	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ talazoparib (MDV3800) for: 1st Line Ovarian Cancer (Biologic) Project advanced	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Cancer (Biologic)	Phase 1	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	2nd Line Non-Small Cell Lung Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Non-Small Cell Lung Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Gastric Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Platinum Resistant/Refractory Ovarian Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Ovarian Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Urothelial Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) (BREAKTHROUGH)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic)	Phase 3	Product Enhancement	Biologic
dacomitinib (PF-00299804) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Pfizer Innovative Health Mechanism of Action: pan-HER Inhibitor Go to clinical trial	1st Line EGFR-activating mutant Non-Small Cell Lung Cancer (ORPHAN - U.S., PRIORITY REVIEW)	Registration	New Molecular Entity	Small Molecule
gedatolisib (PF-05212384) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: Pfizer Innovative Health Mechanism of Action: Phosphatidyl inositol-3 kinase catalytic sub-unit a inhibitor / mammalian target of rapamycin inhibitor (PI3K/mTOR) Go to clinical trial	Cancer	Phase 1	New Molecular Entity	Small Molecule